In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients
Journal of Antimicrobial Chemotherapy , Volume 70 - Issue 4 p. 1072- 1075
Objectives: Trichophyton violaceum is an anthropophilic dermatophyte that is endemic to parts of Africa and Asia and is sporadic in Europe. T. violaceum mainly causes tinea capitis in both children and adolescents. Although the infections caused by T. violaceum are of considerable medical importance, its antifungal susceptibility profile remains poorly examined. Methods: In this study, we tested the in vitro antifungal susceptibility of a set of clinical T. violaceum isolates obtained from tinea capitis patients, using the CLSI broth microdilution method. We tested eight antifungals and used isolates collected from Western China (21), Eastern China (12), the Middle East (1), Europe (20), South Africa (7) and Canada (1). Results: The geometric means of the MICs of the antifungals for all isolates were as follows (in increasing order): posaconazole, 0.021 mg/L; terbinafine, 0.023 mg/L; voriconazole, 0.062 mg/L; amphotericin B, 0.20 mg/L; itraconazole, 0.34 mg/L; caspofungin, 0.56 mg/L; fluconazole, 4.23 mg/L; and flucytosine, 8.46 mg/L. No statistically significant differences in the susceptibility profiles of T. violaceum were detected within the geographical regions tested. Conclusions: Posaconazole, terbinafine and voriconazole were shown to be the most potent antifungal agents against T. violaceum isolates obtained from tinea capitis patients worldwide. These results might help clinicians in developing appropriate therapies that have a high probability of successfully treating tinea capitis due to T. violaceum.
|Antifungal susceptibility testing, Fungus, T. violaceum|
|Journal of Antimicrobial Chemotherapy|
|Organisation||Department of Medical Microbiology and Infectious Diseases|
Deng, S, de Hoog, G.S, Verweij, P.E, Zoll, J, Ilkit, M, Morsali, F, … Seyedmousavi, S. (2014). In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients. Journal of Antimicrobial Chemotherapy, 70(4), 1072–1075. doi:10.1093/jac/dku503